Pages that link to "Q24646237"
Jump to navigation
Jump to search
The following pages link to NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas (Q24646237):
Displaying 50 items.
- Guidelines for the use and interpretation of assays for monitoring autophagy (Q21996341) (← links)
- Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Q22676705) (← links)
- Updates of mTOR inhibitors (Q24607170) (← links)
- The mTOR signalling pathway in human cancer (Q24627306) (← links)
- Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy (Q24628724) (← links)
- Akt and autophagy cooperate to promote survival of drug-resistant glioma (Q24629677) (← links)
- mTOR: from growth signal integration to cancer, diabetes and ageing (Q24633662) (← links)
- Radioresistance of Brain Tumors (Q26752579) (← links)
- PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma (Q26766293) (← links)
- PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer (Q27006181) (← links)
- Will kinase inhibitors make it as glioblastoma drugs? (Q27012684) (← links)
- Dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 has a therapeutic potential and sensitizes cisplatin in nasopharyngeal carcinoma (Q27332333) (← links)
- Targeting the RAS oncogene (Q27687198) (← links)
- mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors (Q27851707) (← links)
- Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives (Q28071388) (← links)
- Glioblastoma-derived Leptin Induces Tube Formation and Growth of Endothelial Cells: Comparison with VEGF Effects (Q28116692) (← links)
- The susceptibility of trypanosomatid pathogens to PI3/mTOR kinase inhibitors affords a new opportunity for drug repurposing (Q28476644) (← links)
- S6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer (Q28477972) (← links)
- Activation of the PI3K/mTOR pathway is involved in cystic proliferation of cholangiocytes of the PCK rat (Q28573157) (← links)
- MRI reveals the in vivo cellular and vascular response to BEZ235 in ovarian cancer xenografts with different PI3-kinase pathway activity. (Q30881669) (← links)
- Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma (Q33591658) (← links)
- Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies (Q33644407) (← links)
- Identification of novel synergistic targets for rational drug combinations with PI3 kinase inhibitors using siRNA synthetic lethality screening against GBM (Q33853600) (← links)
- Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo (Q33945972) (← links)
- Probing the probes: fitness factors for small molecule tools (Q34001269) (← links)
- The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer (Q34038031) (← links)
- Crosstalk between apoptosis and autophagy: molecular mechanisms and therapeutic strategies in cancer (Q34102626) (← links)
- The complexes of mammalian target of rapamycin. (Q34116818) (← links)
- Autophagy-regulating small molecules and their therapeutic applications (Q34147157) (← links)
- NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/mTOR pathway in cisplatin-resistant non-small cell lung carcinoma (Q34170552) (← links)
- MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma (Q34182679) (← links)
- Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group (Q34196216) (← links)
- Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas (Q34291001) (← links)
- The evolution of the TOR pathway and its role in cancer (Q34318188) (← links)
- Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells (Q34480703) (← links)
- NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro (Q34679652) (← links)
- Vertical Targeting of the Phosphatidylinositol-3 Kinase Pathway as a Strategy for Treating Melanoma (Q34682072) (← links)
- Establishment of genetically diverse patient-derived xenografts of colorectal cancer. (Q34704942) (← links)
- Glial progenitors as targets for transformation in glioma (Q34735661) (← links)
- Dual Targeting of Phosphoinositide 3-Kinase and Mammalian Target of Rapamycin Using NVP-BEZ235 as a Novel Therapeutic Approach in Human Ovarian Carcinoma (Q34810176) (← links)
- A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors (Q34818301) (← links)
- NVP-BEZ235 overcomes gefitinib-acquired resistance by down-regulating PI3K/AKT/mTOR phosphorylation (Q35063769) (← links)
- The challenges and the promise of molecular targeted therapy in malignant gliomas (Q35214534) (← links)
- Key autophagic targets and relevant small-molecule compounds in cancer therapy (Q35489073) (← links)
- Drugging the PI3 kinome: from chemical tools to drugs in the clinic. (Q35622141) (← links)
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health (Q35679353) (← links)
- The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses (Q35763894) (← links)
- Efficacy of phosphatidylinositol-3 kinase inhibitors in a primary mouse model of undifferentiated pleomorphic sarcoma (Q35955302) (← links)
- Cell-to-cell variability in PI3K protein level regulates PI3K-AKT pathway activity in cell populations (Q36088956) (← links)
- Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models. (Q36108187) (← links)